Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median effective dose of tegileridine for immediate post-surgical analgesia after laparoscopic colorectal cancer surgery
ChiCTR2500111476Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind, single-arm trial of tegileridine in colorectal cancer (CRC), sponsored by Changhai Hospital. Primary endpoint: Analgesic dose of tegileridine (ED50 and ED95). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500111476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111476.